Under the background that innovation has become the general trend of the development of the pharmaceutical industry, the R&D investment of pharmaceutical companies is increasing
year by year.
According to data, from 2016 to 2021, global pharmaceutical R&D expenditure has risen from US$160 billion to US$212 billion, with a compound annual growth rate of 5.
8%.
It is worth noting that at present, in addition to the pharmaceutical industry, the pharmaceutical equipment field as the upstream of the industrial chain has also ushered in a wave
of R&D innovation.
In the future, pharmaceutical equipment companies will continue to increase investment in research and development (Image source: Pharmaceutical Network)
It is reported that in China, the head pharmaceutical machine companies represented by Chutian Technology and Dongfulong have been continuously increasing investment in research and development, constantly enriching product categories, optimizing product structure, actively deploying new tracks such as biopharmaceuticals and vaccines, and continuously meeting the downstream localization replacement needs while promoting the high-quality development
of the industry.
Specifically, according to the annual report data of two representative head pharmaceutical machine companies, Chutian Technology and Dongfulong, in Q1~3 of 2020/2021/2022, the annual R&D expenses of Dongfulong were 156 million yuan/285 million yuan/232 million yuan, respectively, showing an overall upward trend
.
The annual R&D expenses of Chutian Technology are 288 million yuan/488 million yuan/375 million yuan, respectively, and the company's R&D investment expenses have accounted for about
10% of the annual revenue in recent years.
Among them, in the first half of 2022, Chutian Technology further increased its investment in R&D, which was first manifested in an increase of more than
650 technical R&D personnel over the same period.
Among them, the introduction of technical backbone talents is the focus, and has shown obvious results, and the number of technical research and development personnel of Chutian Group has reached nearly 2,000 during the reporting period
.
At present, pharmaceutical machinery enterprises have produced obvious effects
under the background of the introduction of technology research and development talents, talent management innovation, and increased investment in research and development.
For example, Chutian Technology added 19 new invention patents in the first half of 2022; As of June 30, Chutian Technology and its major domestic subsidiaries have a total of 2,609 valid patents, 20 valid PCT international patents and 203 software copyrights, further highlighting the advantages of technical
reserves.
The industry generally believes that continuing to increase technology research and development has become the general trend
of the development of the pharmaceutical equipment industry.
In fact, many pharmaceutical companies have revealed that they will increase innovation and research and development in
the future.
For example, recently, investors are asking Dongfulong "Will it increase research and development in the main pharmaceutical equipment industry in the future?" When asked, it said that it has been committed to providing high-quality products and solutions closer to the pharmaceutical industry with a global vision and continuous innovation ability, and the company will continue to increase investment in research and development, improve independent innovation capabilities, enhance the company's endogenous growth momentum, drive the company's development with innovation, and improve the company's core competitiveness
.
It is worth mentioning that the current pharmaceutical equipment industry has entered the era of digitalization and intelligence, in order to embrace the new trend, upstream pharmaceutical equipment companies are actively exploring and developing
intelligent, automated, continuous equipment and overall solutions.
It is reported that the biological or sterile preparation production execution system (MES) invested in the research and development of Chutian Technology aims to enhance production compliance and improve enterprise production efficiency, effectively improve paperless office capabilities and production transparent management level, reduce production costs, enhance enterprise information sharing capabilities and mine the value of
production data.
In addition, on December 16, 2022, Chunguang Pharmaceutical held a listing ceremony and officially landed on the Beijing Stock Exchange
.
According to its announcement, the IPO of Chunguang Pharmaceutical Packaging plans to raise about 250 million yuan, which will be used for the construction project of intelligent automation equipment production base and supplementary working capital project
.
In general, the improvement of innovation ability is laying a more solid foundation
for pharmaceutical equipment companies to further grasp the rapid growth of pharmaceutical engineering equipment demand market opportunities.
In the future, while continuing to increase the ability of technological innovation, the manufacturing technology and market expansion ability of pharmaceutical enterprises are expected to continue to improve
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
